Τετάρτη 17 Μαΐου 2017

Antibody that neutralises sMIC boosts CTLA4 immunotherapy response and reduces colitis

Co-administering a monoclonal antibody that neutralises tumour-released soluble MHC I chain-related molecule (sMIC) improves anti-CTLA4 antibody therapy effectiveness and reduces treatment-related colitis, report Medical University of South Carolina...

from #AlexandrosSfakianakis via Alexandros G.Sfakianakis on Inoreader http://ift.tt/2pUA8aK
via IFTTT

Δεν υπάρχουν σχόλια:

Δημοσίευση σχολίου

Δημοφιλείς αναρτήσεις